Wedbush Forecasts Strong Price Appreciation for Scholar Rock (NASDAQ:SRRK) Stock

Scholar Rock (NASDAQ:SRRK) had its price target increased by investment analysts at Wedbush from $56.00 to $58.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Wedbush’s target price indicates a potential upside of 17.98% from the stock’s current price.

Several other equities research analysts have also recently commented on the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Scholar Rock in a research note on Thursday, December 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Scholar Rock in a research note on Thursday, January 22nd. Barclays raised their price target on Scholar Rock from $52.00 to $53.00 and gave the company an “overweight” rating in a report on Tuesday, March 3rd. JPMorgan Chase & Co. boosted their price objective on Scholar Rock from $47.00 to $50.00 and gave the stock an “overweight” rating in a report on Monday, March 16th. Finally, HC Wainwright restated a “buy” rating and set a $58.00 target price on shares of Scholar Rock in a research report on Tuesday, March 3rd. Four investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $54.93.

Scholar Rock Price Performance

Shares of SRRK stock opened at $49.16 on Wednesday. Scholar Rock has a 1 year low of $22.71 and a 1 year high of $50.50. The firm’s 50 day moving average is $45.11 and its 200-day moving average is $40.62. The firm has a market capitalization of $5.65 billion, a price-to-earnings ratio of -14.33 and a beta of 0.70. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.41.

Scholar Rock (NASDAQ:SRRK) last issued its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.76) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.10. During the same quarter last year, the business posted ($0.64) earnings per share. Sell-side analysts forecast that Scholar Rock will post -2.42 EPS for the current fiscal year.

Insider Activity

In related news, insider Jing L. Marantz sold 4,157 shares of the firm’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $46.53, for a total transaction of $193,425.21. Following the sale, the insider owned 126,012 shares of the company’s stock, valued at approximately $5,863,338.36. This trade represents a 3.19% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Mo Qatanani sold 8,484 shares of Scholar Rock stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $47.07, for a total value of $399,341.88. Following the transaction, the insider owned 98,445 shares in the company, valued at approximately $4,633,806.15. This represents a 7.93% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 207,464 shares of company stock worth $9,157,423 over the last three months. Company insiders own 13.30% of the company’s stock.

Institutional Investors Weigh In On Scholar Rock

Large investors have recently modified their holdings of the business. Invesco Ltd. lifted its holdings in shares of Scholar Rock by 21.0% during the 4th quarter. Invesco Ltd. now owns 82,462 shares of the company’s stock valued at $3,632,000 after purchasing an additional 14,291 shares in the last quarter. Mercer Global Advisors Inc. ADV acquired a new stake in Scholar Rock during the 4th quarter worth approximately $308,000. Mackenzie Financial Corp acquired a new stake in Scholar Rock during the 4th quarter worth approximately $221,000. Empowered Funds LLC bought a new position in Scholar Rock in the fourth quarter valued at approximately $114,000. Finally, KVP Capital Advisors LP bought a new position in Scholar Rock in the fourth quarter valued at approximately $1,982,000. 91.08% of the stock is currently owned by institutional investors.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).